20/20 Biolabs annual return on equity
2024
2025
20/20 Biolabs Return on Equity (ROE) Growth & History (AIDX)
20/20 Biolabs's return on equity was −503.12% for fiscal 2025.
View full 20/20 Biolabs company overview20/20 Biolabs annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −503.12% | −311.45 pp |
| 2024 | 2024-12-31 | −191.67% | — |
20/20 Biolabs quarterly return on equity
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −72.18% | — |
| Q1 2026 | 2026-03-31 | −171.68% | — |
| Q4 2025 | 2025-12-31 | −2,931.20% | — |
| Q3 2025 | 2025-09-30 | −102.30% | — |
20/20 Biolabs return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, 20/20 Biolabs's return on equity decreased from −191.67% to −503.12%, a change of −311.45 percentage points. The latest reported quarter, Q2 2026, shows −72.18%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 20/20 Biolabs source filings ↗